Skip to content
medxy logo

Medxy AI

  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
Decade-Long Insights into Deferred Versus Immediate Stenting in STEMI Patients: DANAMI-3-DEFER Trial Findings
Posted inCardiology Specialties

Decade-Long Insights into Deferred Versus Immediate Stenting in STEMI Patients: DANAMI-3-DEFER Trial Findings

Posted by MedXY By MedXY 08/17/2025
The 10-year DANAMI-3-DEFER study compared deferred stenting to immediate stenting in STEMI, showing no mortality benefit but reduced heart failure hospitalizations with deferred stenting.
Read More
Early TAVR Benefits in Asymptomatic Severe Aortic Stenosis: Insights from Cardiac Biomarker Analysis in the EARLY TAVR Trial
Posted inCardiology news Specialties

Early TAVR Benefits in Asymptomatic Severe Aortic Stenosis: Insights from Cardiac Biomarker Analysis in the EARLY TAVR Trial

Posted by MedXY By MedXY 08/17/2025
Cardiac biomarkers NT-proBNP and hs-cTnT predict higher risk in asymptomatic severe aortic stenosis, but early TAVR benefits patients regardless of biomarker levels, with greater relative advantage seen in those with lower biomarker concentrations.
Read More
Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial
Posted inCardiology Diabetes & Endocrinology news Specialties

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

Posted by MedXY By MedXY 08/17/2025
The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.
Read More
Advancements in Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: Insights from the TRILUMINATE Pivotal Trial
Posted inCardiology Specialties

Advancements in Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: Insights from the TRILUMINATE Pivotal Trial

Posted by MedXY By MedXY 08/17/2025
Transcatheter edge-to-edge repair (TEER) offers a safe, effective option to reduce tricuspid regurgitation severity, improve quality of life, and lower heart failure hospitalizations up to two years, including in patients with cardiac implantable electronic device leads.
Read More
Inclisiran Shows Promise for Adolescents with Homozygous Familial Hypercholesterolemia: Results from the ORION-13 Trial
Posted inCardiology Specialties

Inclisiran Shows Promise for Adolescents with Homozygous Familial Hypercholesterolemia: Results from the ORION-13 Trial

Posted by MedXY By MedXY 08/17/2025
The ORION-13 trial demonstrates that inclisiran significantly lowers LDL cholesterol by 33.3% and is safe and well tolerated in adolescents with homozygous familial hypercholesterolemia, addressing an unmet pediatric treatment need.
Read More
Renal Denervation Shows Sustained Blood Pressure Reduction and Safety Over 24 Months in SPYRAL HTN-ON MED Trial
Posted inCardiology Clinical Updates General Surgery news Specialties

Renal Denervation Shows Sustained Blood Pressure Reduction and Safety Over 24 Months in SPYRAL HTN-ON MED Trial

Posted by MedXY By MedXY 08/17/2025
The SPYRAL HTN-ON MED trial demonstrates that renal denervation provides significant long-term reductions in both ambulatory and office systolic blood pressure with good safety, supporting its role in managing hypertension.
Read More
Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial
Posted inCardiology news Specialties

Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial

Posted by MedXY By MedXY 08/17/2025
The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor identification.
Read More
Edoxaban as a Safe and Effective Anticoagulant Early After Bioprosthetic Valve Replacement: Insights from the ENBALV Trial
Posted inCardiology Specialties

Edoxaban as a Safe and Effective Anticoagulant Early After Bioprosthetic Valve Replacement: Insights from the ENBALV Trial

Posted by MedXY By MedXY 08/17/2025
The ENBALV randomized trial demonstrates that edoxaban offers a potential safe and efficacious alternative to warfarin for anticoagulation within three months after surgical bioprosthetic valve replacement, with comparable thromboembolic event rates and a distinct safety profile.
Read More
ADVANTAGE AF Phase 2: Evaluating Pulsed Field Ablation for Persistent Atrial Fibrillation Using Continuous ECG Monitoring
Posted inCardiology news Specialties

ADVANTAGE AF Phase 2: Evaluating Pulsed Field Ablation for Persistent Atrial Fibrillation Using Continuous ECG Monitoring

Posted by MedXY By MedXY 08/17/2025
The ADVANTAGE AF Phase 2 study demonstrates pulsed field ablation's safety and efficacy for persistent atrial fibrillation, introducing continuous cardiac monitoring to better assess arrhythmia burden and outcomes over one year.
Read More
Long-Term Safety of Subcutaneous vs. Transvenous ICDs: Results from the PRAETORIAN-XL Trial
Posted inCardiology Specialties

Long-Term Safety of Subcutaneous vs. Transvenous ICDs: Results from the PRAETORIAN-XL Trial

Posted by MedXY By MedXY 08/17/2025
The PRAETORIAN-XL trial shows subcutaneous ICDs have fewer major and lead-related complications than transvenous ICDs over 8 years, suggesting S-ICD as a safer option for patients without pacing needs.
Read More
Optimizing Sedation for Pulsed-Field Ablation in Atrial Fibrillation: Results of the COOPERATIVE-PFA Trial
Posted inCardiology news Specialties

Optimizing Sedation for Pulsed-Field Ablation in Atrial Fibrillation: Results of the COOPERATIVE-PFA Trial

Posted by MedXY By MedXY 08/17/2025
This randomized trial compares sedation regimens for pulsed-field ablation in atrial fibrillation, finding remimazolam-ketamine deep analgosedation superior to propofol-opioid approaches in reducing hypoxemia and hypotension.
Read More
High-Dose Statins and Their Impact on the Progression of Small Abdominal Aortic Aneurysms: Insights from a 5-Year Danish Cohort Study
Posted inCardiology Clinical Updates news Specialties

High-Dose Statins and Their Impact on the Progression of Small Abdominal Aortic Aneurysms: Insights from a 5-Year Danish Cohort Study

Posted by MedXY By MedXY 08/17/2025
This 5-year prospective cohort study reveals that high-dose statin therapy significantly slows abdominal aortic aneurysm growth and reduces the risks of repair, rupture, and death in men, suggesting benefits beyond traditional cardiovascular risk management.
Read More
Unraveling the Link Between Somatic JAK2V617F Mutation and Ascending Aortic Aneurysms: Evidence from a Large-Scale Cardiovascular Screening
Posted innews Rheumatology Specialties

Unraveling the Link Between Somatic JAK2V617F Mutation and Ascending Aortic Aneurysms: Evidence from a Large-Scale Cardiovascular Screening

Posted by MedXY By MedXY 08/17/2025
A multicenter Danish study reveals a strong independent association between somatic JAK2V617F mutation—especially its variant allele frequency—and risk of ascending aortic aneurysms, suggesting targeted screening strategies.
Read More
Evaluating Electronic Nudges to Enhance Guideline-Directed Therapy in Chronic Kidney Disease: Insights from the NUDGE-CKD Trial
Posted inAI Clinical Updates Nephrology news Specialties

Evaluating Electronic Nudges to Enhance Guideline-Directed Therapy in Chronic Kidney Disease: Insights from the NUDGE-CKD Trial

Posted by MedXY By MedXY 08/16/2025
The NUDGE-CKD trial found that electronic letter-based nudges to patients with chronic kidney disease and their general practitioners did not significantly improve initiation of guideline-recommended medications over usual care.
Read More
Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial
Posted inCardiology Clinical Updates news Specialties

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial

Posted by MedXY By MedXY 08/16/2025
The AZALEA-TIMI 71 trial shows abelacimab, a novel factor XI inhibitor, reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients on antiplatelet therapy, suggesting a safer anticoagulation alternative.
Read More
High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI
Posted inCardiology Clinical Updates news Specialties

High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI

Posted by MedXY By MedXY 08/16/2025
This study examines the morphology of high-risk plaques in non-culprit coronary lesions among NSTEMI and STEMI patients and their impact on clinical outcomes, suggesting comparable prevalence of high-risk features but differing plaque characteristics between these groups.
Read More
Enhancing Cardiovascular Risk Prediction and Outcomes with Coronary CT Angiography: Insights from the PROMISE and SCOT-HEART Trials
Posted inCardiology news Specialties

Enhancing Cardiovascular Risk Prediction and Outcomes with Coronary CT Angiography: Insights from the PROMISE and SCOT-HEART Trials

Posted by MedXY By MedXY 08/16/2025
Coronary CTA, guided by clinical risk models and advanced radiomic plaque analysis, improves prediction and prevention of myocardial infarction in patients with new-onset chest pain, particularly in those with low clinical likelihood of coronary artery disease.
Read More
Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial
Posted inCardiology Diabetes & Endocrinology Nephrology Specialties

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

Posted by MedXY By MedXY 08/16/2025
The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.
Read More
Revolutionizing Acute Myocardial Infarction Diagnosis: Insights from a New Clinical Classification Using Cardiac Imaging
Posted inCardiology Clinical Updates news Radiology Specialties

Revolutionizing Acute Myocardial Infarction Diagnosis: Insights from a New Clinical Classification Using Cardiac Imaging

Posted by MedXY By MedXY 08/16/2025
A novel clinical classification incorporating cardiac imaging refines diagnosis of acute myocardial infarction, distinguishing spontaneous, secondary, and non-infarction cases, improving risk stratification and guiding targeted treatment.
Read More
Pregnancies Following Peri-Partum Cardiomyopathy: Insights from the ESC EuroObservational Research Programme
Posted inCardiology OB/GYN & Women's Health Specialties

Pregnancies Following Peri-Partum Cardiomyopathy: Insights from the ESC EuroObservational Research Programme

Posted by MedXY By MedXY 08/16/2025
This study analyses maternal and neonatal outcomes in subsequent pregnancies after peri-partum cardiomyopathy (PPCM), revealing lower than expected maternal risks and suggesting potential reclassification of pregnancy risk categories based on ventricular function.
Read More

Posts pagination

Previous page 1 … 158 159 160 161 162 … 197 Next page
  • Safety First: Concurrent Metastases-Directed Stereotactic Radiotherapy and Biological Therapy Show Low Risk of Severe Adverse Events
  • Environmental Cardiotoxicity: PM2.5 and Ozone Exposure Double the Risk of Cardiac Dysfunction in Breast Cancer Patients
  • Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer
  • Moving Beyond Birthdays: Five-Year Absolute Risk-Based Screening Outperforms Age-Based Mammography
  • Beyond the Count: How Product Factors and High Thresholds Shape Pediatric Platelet Transfusion Outcomes
Post You Might Like
Posted innews Oncology Radiology
Safety First: Concurrent Metastases-Directed Stereotactic Radiotherapy and Biological Therapy Show Low Risk of Severe Adverse Events
Posted by MedXY By MedXY 02/09/2026
Posted inCardiology news Oncology
Environmental Cardiotoxicity: PM2.5 and Ozone Exposure Double the Risk of Cardiac Dysfunction in Breast Cancer Patients
Posted by MedXY By MedXY 02/09/2026
Posted innews Oncology Urology
Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer
Posted by MedXY By MedXY 02/09/2026
Posted innews Oncology Radiology
Moving Beyond Birthdays: Five-Year Absolute Risk-Based Screening Outperforms Age-Based Mammography
Posted by MedXY By MedXY 02/09/2026
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in